Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFZ533 in de novo kidney transplant recipients
NL-OMON45886Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of iscalimab in kidney transplant (3 arms), sponsored by Novartis. Primary endpoints: Treated biopsy proven acute rejection, Graft loss and 14 more. Started Aug 2016; status: recruiting.
02
Drugs
iscalimab
03
Conditions
kidney transplant
Beyond the preview
Go deeper on NL-OMON45886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45886.